• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎中的OX40L - OX40信号传导

OX40L-OX40 Signaling in Atopic Dermatitis.

作者信息

Furue Masutaka, Furue Mihoko

机构信息

Department of Dermatology, Kyushu University, Higashiku, Fukuoka 812-8582, Japan.

1-19-20 Momochi, Sawara-ku, Fukuoka 814-0006, Japan.

出版信息

J Clin Med. 2021 Jun 11;10(12):2578. doi: 10.3390/jcm10122578.

DOI:10.3390/jcm10122578
PMID:34208041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8230615/
Abstract

OX40 is one of the co-stimulatory molecules expressed on T cells, and it is engaged by OX40L, primarily expressed on professional antigen-presenting cells such as dendritic cells. The OX40L-OX40 axis is involved in the sustained activation and expansion of effector T and effector memory T cells, but it is not active in naïve and resting memory T cells. Ligation of OX40 by OX40L accelerates both T helper 1 (Th1) and T helper 2 (Th2) effector cell differentiation. Recent therapeutic success in clinical trials highlights the importance of the OX40L-OX40 axis as a promising target for the treatment of atopic dermatitis.

摘要

OX40是一种在T细胞上表达的共刺激分子,它与主要在专业抗原呈递细胞(如树突状细胞)上表达的OX40L结合。OX40L-OX40轴参与效应T细胞和效应记忆T细胞的持续激活和扩增,但在初始和静止记忆T细胞中不活跃。OX40L与OX40的结合加速了辅助性T细胞1(Th1)和辅助性T细胞2(Th2)效应细胞的分化。近期临床试验中的治疗成功突出了OX40L-OX40轴作为特应性皮炎治疗的一个有前景靶点的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/8230615/334ba30b1154/jcm-10-02578-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/8230615/ee6d7b7341b1/jcm-10-02578-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/8230615/334ba30b1154/jcm-10-02578-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/8230615/ee6d7b7341b1/jcm-10-02578-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0796/8230615/334ba30b1154/jcm-10-02578-g002.jpg

相似文献

1
OX40L-OX40 Signaling in Atopic Dermatitis.特应性皮炎中的OX40L - OX40信号传导
J Clin Med. 2021 Jun 11;10(12):2578. doi: 10.3390/jcm10122578.
2
The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.OX40 配体/OX40 轴信号在特应性皮炎中的作用。
Br J Dermatol. 2024 Sep 18;191(4):488-496. doi: 10.1093/bjd/ljae230.
3
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis.OX40-OX40L轴在特应性皮炎发病机制中的作用
Dermatitis. 2025 Jan-Feb;36(1):28-36. doi: 10.1089/derm.2024.0058. Epub 2024 May 3.
4
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis.一个非比寻常的故事:OX40 和 OX40L 在特应性皮炎中的作用。
Cells. 2024 Mar 28;13(7):587. doi: 10.3390/cells13070587.
5
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.OX40-OX40L抑制疗法治疗特应性皮炎——聚焦于罗卡替尼单抗和阿利替尼单抗。
Pharmaceutics. 2022 Dec 8;14(12):2753. doi: 10.3390/pharmaceutics14122753.
6
OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.OX40L/OX40 轴可损害人类 SLE 中的滤泡性和天然 Treg 功能。
JCI Insight. 2018 Dec 20;3(24):122167. doi: 10.1172/jci.insight.122167.
7
IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand.白细胞介素-33通过增强OX40配体的功能促进Th2免疫反应的诱导和维持。
Allergol Int. 2014;63(3):443-455. doi: 10.2332/allergolint.13-OA-0672. Epub 2015 Feb 27.
8
Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.OX40(CD134)的结扎调节异基因骨髓移植受者的移植物抗宿主病(GVHD)和移植排斥反应。
Blood. 2003 May 1;101(9):3741-8. doi: 10.1182/blood-2002-10-3048. Epub 2003 Jan 9.
9
Research progress in OX40/OX40L in allergic diseases.OX40/OX40L在过敏性疾病中的研究进展
Int Forum Allergy Rhinol. 2024 Dec;14(12):1921-1928. doi: 10.1002/alr.23469. Epub 2024 Oct 15.
10
The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis.OX40 轴与特应性皮炎的全身性和局部受累均有关联。
Acta Derm Venereol. 2020 Mar 31;100(6):adv00099. doi: 10.2340/00015555-3452.

引用本文的文献

1
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.罗卡替尼单抗:一种针对特应性皮炎中OX40受体的新型T细胞再平衡疗法。
Dermatol Ther (Heidelb). 2025 Sep 6. doi: 10.1007/s13555-025-01492-1.
2
Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.特应性皮炎的管理:从传统疗法到生物标志物驱动的治疗方法。
Biomol Ther (Seoul). 2025 Sep 1;33(5):813-829. doi: 10.4062/biomolther.2025.081. Epub 2025 Aug 19.
3
Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches.

本文引用的文献

1
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.度普利尤单抗可改善中重度特应性皮炎成人的哮喘和鼻-鼻窦结局。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212-1223.e6. doi: 10.1016/j.jaip.2020.12.059. Epub 2021 Jan 13.
2
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.抗 PD-1 和抗 CTLA-4 检查点阻断联合治疗:黑色素瘤的治疗和免疫作用机制。
Eur J Immunol. 2021 Mar;51(3):544-556. doi: 10.1002/eji.202048747. Epub 2021 Feb 23.
3
Fms-Like Tyrosine Kinase 3-Independent Dendritic Cells Are Major Mediators of Th2 Immune Responses in Allergen-Induced Asthmatic Mice.
特应性皮炎的治疗策略进展:新兴靶点与个性化方法
Biomolecules. 2025 Jun 8;15(6):838. doi: 10.3390/biom15060838.
4
A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40 T cells.一种新型抗OX40人单克隆抗体,可阻断OX40/OX40L信号传导并消耗OX40 T细胞。
Mar Life Sci Technol. 2025 Apr 7;7(2):328-339. doi: 10.1007/s42995-025-00284-y. eCollection 2025 May.
5
OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review.OX40/OX40L作为特应性皮炎的治疗靶点:一项范围综述
Biologics. 2025 May 2;19:281-288. doi: 10.2147/BTT.S511125. eCollection 2025.
6
Type 2 Inflammation and Its Role in Dermatologic Diseases.2型炎症及其在皮肤病中的作用。
Int J Dermatol. 2025 Jun;64(6):978-991. doi: 10.1111/ijd.17707. Epub 2025 Mar 22.
7
OX40 ligand promotes follicular helper T cell differentiation and development in mice with immune thrombocytopenia.OX40配体促进免疫性血小板减少症小鼠中滤泡辅助性T细胞的分化和发育。
J Zhejiang Univ Sci B. 2025 Mar 6;26(3):240-253. doi: 10.1631/jzus.B2300947.
8
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.ROCKET:一项评估罗卡替尼单抗治疗中度至重度特应性皮炎疗效和安全性的3期研究项目。
Immunotherapy. 2025 Feb;17(2):83-94. doi: 10.1080/1750743X.2025.2464528. Epub 2025 Feb 26.
9
Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.可激活T淋巴细胞上OX40的OX40配体融合蛋白的产生与特性分析
Front Immunol. 2025 Jan 10;15:1473815. doi: 10.3389/fimmu.2024.1473815. eCollection 2024.
10
A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab.作为特应性皮炎潜在治疗靶点的OX40-OX40L通路的叙述性综述:聚焦于罗卡替尼单抗和阿利特利单抗。
Dermatol Ther (Heidelb). 2024 Dec;14(12):3197-3210. doi: 10.1007/s13555-024-01308-8. Epub 2024 Nov 20.
Fms 样酪氨酸激酶 3 非依赖性树突状细胞是变应原诱导哮喘小鼠 Th2 免疫应答的主要介导者。
Int J Mol Sci. 2020 Dec 14;21(24):9508. doi: 10.3390/ijms21249508.
4
Overcoming Immune Evasion in Melanoma.克服黑色素瘤的免疫逃逸。
Int J Mol Sci. 2020 Nov 26;21(23):8984. doi: 10.3390/ijms21238984.
5
Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis.通过芳烃受体(AHR)轴与白细胞介素-13/白细胞介素-4-JAK-信号转导及转录激活因子6/信号转导及转录激活因子3(IL-13/IL-4‒JAK‒STAT6/STAT3)轴之间的竞争对皮肤屏障功能进行调节:对特应性皮炎的致病及治疗意义
J Clin Med. 2020 Nov 20;9(11):3741. doi: 10.3390/jcm9113741.
6
Combination blockade of OX40L and CD30L inhibits allergen-driven memory T2 cell reactivity and lung inflammation.联合阻断 OX40L 和 CD30L 可抑制变应原驱动的记忆 T2 细胞反应和肺部炎症。
J Allergy Clin Immunol. 2021 Jun;147(6):2316-2329. doi: 10.1016/j.jaci.2020.10.037. Epub 2020 Nov 5.
7
Basics and recent advances in the pathophysiology of atopic dermatitis.特应性皮炎的病理生理学基础及最新进展。
J Dermatol. 2021 Feb;48(2):130-139. doi: 10.1111/1346-8138.15664. Epub 2020 Oct 29.
8
T-cell agonists in cancer immunotherapy.癌症免疫疗法中的 T 细胞激动剂。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000966.
9
Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.免疫检查点阻断与非小细胞肺癌临床应答的生物标志物。
Scand J Immunol. 2020 Dec;92(6):e12980. doi: 10.1111/sji.12980. Epub 2020 Oct 24.
10
Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.在日本中重度特应性皮炎患者中,重复静脉输注 KHK4083(一种全人源抗 OX40 单克隆抗体)的安全性、耐受性和疗效。
J Dermatol Sci. 2020 Aug;99(2):82-89. doi: 10.1016/j.jdermsci.2020.06.005. Epub 2020 Jun 13.